2 - 4 September 2010, Istanbul, Turkey

Course Objectives

• Describe public health aspects of influenza epidemics and pandemics
• Emphasize the importance of influenza infections and address problems related to: Diagnosis of infections with current subtypes, detection of emerging subtypes and misuse of antivirals and antibiotics
• Increase awareness
• Address the economical burden caused by influenza viruses

Course Venue

Armada Hotel
Ahirkapi Sokak. No: 24
34122 Sultanahmet
Istanbul, Turkey

Target Audience

150-200 participants including, but not limited to, infectious disease specialists and microbiologists from Europe, Middle East and beyond.

Registration Procedure

Please download the registration form (see right column) and return it to the course administrative secretariat or follow the link on the right until 15 August 2010.

Registration Fee

EUR 350 for ESCMID and Turkish Microbiological Society members

EUR 450 for all others

The fee includes participation to the scientific sessions, printed material, lunches and coffee breaks. Travel and accommodation costs are not included.

CME Accreditation

The organizer of the course will apply for European CME accreditation through EACCME.

Contact Person (educational programme): 

Selim Badur
S. Badur

Meral Akcay Ciblak
M. Ciblak

Administrative Secretariat

K2 Conference & Event Management Co.Munir Nurettin Selcuk Str. No:70/2 Kalamis 34724 Kadikoy/Istanbul

Phone +90 216 449 49 45
Fax +90 216 449 64 10

email

Influenza Viruses

• Influenza pandemics: historical perspective. C. Hannoun
• Love in the time of H1N1: Challenges and lessons learnt. U Kartoglu
• Origin and evolution of influenza viruses. A. Osterhaus
• Biology of influenza viruses. B. Lina
• Epidemiology and molecular epidemiology of influenza viruses. A. Hay

Surveillance

• Influenza surveillance. J.-M. Cohen
• Methods to identify increased influenza activity. P. Froom
• Laboratory diagnosis of influenza viruses. M. Rothberg

Pathogenesis-immunology 

• Antiviral innate immunity mechanisms in the lung mucosa: the flu as an example. M. Si-Tahar
• Influenza pathogenesis and adaptive immune response. E. Wissinger
• Mechanisms underlying the constitutional symptoms of influenza. C. Sweet

Prevention

• Influenza vaccines and vaccine development. S. Sambhara
• Immunogenicity, safety and use of H1N1 vaccines in Europe. P. Van Damme

Treatment

• Current anti-virals and resistance. M. de Jong
• Novel antiviral strategies and development. S. Sambhara
• A 21st century approach to severe influenza: treating the host. D. Fedson

H1N1 pandemic: Turkish experience

• The course of pandemic influenza H1N1 in children: Turkey. M. Bakir
• Sequence analysis of influenza isolates from selected patients. M. Hasoksuz
• Epidemiological features and clinical course of H1N1 infections among adults. O. Ergonul
• 2009-2010 pandemic: Turkish laboratory experience. M.A. Ciblak 

Course Faculty

• Mustafa Bakır, Istanbul, TR
• Meral Akcay Ciblak, Istanbul, TR
• Jean-Marie Cohen, Paris, FR
• Onder Ergonul, Istanbul, TR
• David Fedson, Sergy Haut, FR
• Paul Froom, Tel Aviv, IL
• Claude Hannoun, Paris, FR
• Umit Kartoglu, Geneva, CH
• Mustafa Hasoksuz, Istanbul, TR
• Alan Hay, London, UK
• Menno de Jong, Amsterdam, NL
• Bruno Lina, Lyon, FR
• Albert Osterhaus, Rotterdam, NL
• Michael Rothberg, Springfield, MA, US
• Suryaprakash Sambhara, Atlanta, GA, USA
• Mustapha Si-Tahar, Paris, FR
• Clive Sweet, Birmingham, UK
• Pierre Van Damme, Antwerp, BE
• Erica Wissinger, London, UK